We defined melanoma patients who had received MSKCC-IMPACT testing and at least one dose of ICIs as the MSKCC-IO cohort; the characteristics of the 14 patients with CCND1 amplification in the MSKCC-IO cohort are shown in Table S2. This evidence concerns the gene CCND1 and melanoma.